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Abstract
Background: Prevalence of malnutrition in older hospitalized patients is 30%. Malnutrition is associated with poor
clinical outcomes in terms of high morbidity and mortality and is costly for hospitals. Extended nutrition interventions
improve clinical outcomes but limited studies have investigated whether these interventions are cost-effective.
Methods: In this randomized controlled trial, 148 malnourished general medical patients ≥60 years were recruited and
randomized to receive either an extended nutritional intervention or usual care. Nutrition intervention was individualized
and started with 24 h of admission and was continued for 3 months post-discharge with a monthly telephone
call whereas control patients received usual care. Nutrition status was confirmed by Patient generated subjective
global assessment (PG-SGA) and health-related quality of life (HRQoL) was measured using EuroQoL 5D (EQ-5D-5 L)
questionnaire at admission and at 3-months follow-up. A cost-effectiveness analysis was conducted for the primary
outcome (incremental costs per unit improvement in PG-SGA) while a cost-utility analysis (CUA) was undertaken for
the secondary outcome (incremental costs per quality adjusted life year (QALY) gained).
Results: Nutrition status and HRQoL improved in intervention patients. Mean per included patient Australian Medicare
costs were lower in intervention group compared to control arm (by $907) but these differences were not statistically
significant (95% CI: -$2956 to $4854). The main drivers of higher costs in the control group were higher inpatient
($13,882 versus $13,134) and drug ($838 versus $601) costs. After adjusting outcomes for baseline differences and
repeated measures, the intervention was more effective than the control with patients in this arm reporting QALYs
gained that were higher by 0.0050 QALYs gained per patient (95% CI: -0.0079 to 0.0199). The probability of
the intervention being cost-effective at willingness to pay values as low as $1000 per unit improvement in
PG-SGA was > 98% while it was 78% at a willingness to pay $50,000 per QALY gained.
Conclusion: This health economic analysis suggests that the use of extended nutritional intervention in older
general medical patients is likely to be cost-effective in the Australian health care setting in terms of both primary and
secondary outcomes.
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Background
Malnutrition is common in older hospitalized patients
with prevalence rates as high as 30% in acute care settings
in Australia [1]. Malnutrition is associated with adverse
clinical outcomes for patients in terms of higher morbidity
and mortality [2] and is costly for the hospitals [3]. The
adverse effects associated with malnutrition on patient
outcome and recovery results in increased health care use
and costs [4]. Health-care costs are increased because
malnourished patients stay longer in hospitals, suffer more
infectious and non-infectious nosocomial complications,
experience frequent hospital re-admissions and have
higher utilization of health-care resources in the commu-
nity [5–8]. Three recent meta-analyses [9–11] have indi-
cated that nutrition intervention has economic benefits
but have also suggested that there is a need for further
high quality studies to confirm these findings in different
age groups and in different health care settings. This is
especially so as majority of these studies have been
conducted in Europe and very few studies are available in
the Australian health care settings.
A recent randomized controlled trial [12] conducted in
a large tertiary hospital in Australia from 2014 to 2016,
assessed efficacy of an early and extended nutrition inter-
vention in older hospitalized patients. In this trial, an indi-
vidualized nutrition intervention was started within 24 h
of hospital admission and patients ≥60 years age received
monthly telehealth follow up for two months following
discharge and this intervention was compared to usual
care. The main objectives in this trial was to examine
whether such an intervention could improve nutritional
status and quality of care by reducing adverse clinical out-
comes and optimizing use of existing resources.
This trial found a trend towards an improvement in nu-
tritional status and quality of life and a significant reduc-
tion in length of hospital stay but there was no reduction
in mortality or readmissions at 3 months follow up. Al-
though the resources needed for the intervention were
modest and the anticipated improvement in the nutrition
status was small [12], no economic evaluation was con-
ducted to examine whether the intervention was worth
pursuing from an economic perspective. The objective of
the present analysis was to conduct an economic evalu-
ation that assessed whether the individualized nutrition
intervention was value for money when considered
from a healthcare sector (Australian Medicare) perspec-
tive. The results of the evaluation will help determine
whether allocation of resources for improvement of
nutritional status of older hospitalized patients is justi-
fiable. Consequently, the primary outcome of this
evaluation was expressed in terms of incremental costs
per unit improvement in the PG-SGA (CEA) and the
secondary outcome reported in terms of incremental
costs per QALY gained (CUA).
Methods
Study design
The data for this health economic analysis were
obtained from a recently conducted nutrition inter-
vention study [12], which was designed as a random-
ized controlled trial.
Target population
The participants for this study included hospitalized pa-
tients aged ≥60 years, who were confirmed as malnour-
ished by a qualified dietitian using PG-SGA tool [13].
Sample size
The sample size was calculated based upon the change
in the PG-SGA score from the baseline in the clinical
trial [12] which provided data for this economic evalu-
ation. The sample size in the clinical trial was based on
the findings of a previous study [14], which has sug-
gested that a shift of 3 (SD 4.1) in PG-SGA is clinically
meaningful, assuming an affect size of 0.35, alpha = 0.05
and power of 80% the estimated sample size was 86 (43
in each group) was calculated to be sufficient.
Setting and location
This study included patients presenting to the Depart-
ment of General Medicine, Flinders Medical Centre
(FMC), Adelaide, South Australia. FMC is a tertiary
level, teaching hospital with 520 beds capacity and the
Department of General Medicine admits approximately
4500 patients per year. Health services at FMC are pre-
dominantly funded through the Australian Medicare
Scheme (the primary funder of universal healthcare in-
surance in Australia). Patients were excluded if they
were receiving palliative care, residing in rural areas, or
were of indigenous origin or were non-English speaking.
Rural, indigenous and non-English speaking subjects
were excluded due to lack of funds to travel to rural
areas for assessments and seek services of an Indigenous
liaison officer/interpreter.
Study perspective
The direct costs of implementing nutritional interven-
tion were determined from the Australian (Medicare)
health care perspective. These included costs of hospital-
izations, dietitian costs for post-discharge telephone
calls, costs of providing nutrition supplements, post-dis-
charge general practioner (GP) and specialist phys-
ician visits. Other costs were for any outpatient
investigations and procedures, allied health care utilization
and medicinal products over the period of 3-months of
intervention. Indirect costs, such as those incurred by the
patients due to loss of productivity were not included in
this analysis.
Sharma et al. BMC Geriatrics  (2018) 18:41 Page 2 of 13
Comparators
The economic evaluation determined the relative cost-
effectiveness/cost-utility of the intervention when com-
pared to the control.
Intervention
Nutrition intervention was initiated within 24 h of hos-
pital admission and aimed to meet 100% of patients’ en-
ergy and protein requirements for ideal body weight,
calculated using commonly adopted predictive equations
[15] along with an adequate intake of essential vitamins
and minerals. Intervention patients received an individu-
alized nutrition intervention by the dietitian, depending
upon their underlying medical conditions, protein, en-
ergy, vitamin and mineral requirements and food prefer-
ences. Nutritional strategies employed by the dietitian
included provision of oral nutrition supplements (ONS)
(1–2.2 kcal/ml and 0.05–0.12 g of protein/ml), mid-meal
snacks and food fortification with consideration given to
individual patients’ food preferences and taste. The ONS
utilized were Resource (Nestle Heath Science) (475 kcal,
19.7 g protein) and Sustagen (Nestle Heath Science)
(248 kcal, 12.5 g protein), which in addition to protein
provided a range of nutrients. Multivitamins were not
separately prescribed but were left to the discretion of
the treating clinicians. In addition, the patients and their
care-providers received dietetic counseling, to augment
their energy intake by using a range of strategies includ-
ing recommendation of energy and nutrient dense food
items, increasing the number of meals they ate, and con-
sumption of energy, protein and nutrient-rich snacks.
Patients who needed assistance with meals were flagged,
so that a ward based staff member provided help during
meals. The frequency of contact between patient and
dietitian during the hospital stay varied depending upon
individual patients’ needs and the length of hospital stay.
If the dietitian thought that the patient was unable to
achieve their daily energy and nutrient requirements
then they received almost daily input. Where patients
were discharged to a nursing home then the dietitian
contacted the nursing home manager and forwarded the
recommended nutritional care plan to be followed. The
hospital covered the cost of commercial oral nutritional
supplements at the time of discharge for patients where
≥50% of the patient’s daily energy requirements were
determined to be required from supplements. All inter-
vention patients were contacted by a monthly telephone
call by the research dietitian for 2 months. During this
interview, a structured format was used by the dietitian
to collect information about patients’ recent weight,
compliance with the dietetic plan and any side effects
with supplementation. In addition, patients received
dietetic counseling with a focus to reinforce compliance
with the intervention. Compliance with the dietetic plan
was assessed by using a 24-h self-reported dietary recall.
In this trial, the dietitian assessed the patients as compli-
ant to the nutritional care plan if they were able to meet
at least 75% of their energy and protein requirements.
Control group
Patients randomized to the control group followed usual
care currently operative in Flinders Medical Centre. Cur-
rently all patients undergo nutrition screening by the use
of Malnutrition Universal Screening Tool (MUST) and
patients identified as high risk for malnutrition are re-
ferred to the dietitian. However, dietetic input occurs only
if clinicians refer the patients and even if a dietitian sees
them during hospital admission, they may not be followed
after discharge. In this study, the control patients were
flagged as malnourished and this was documented in the
case notes for clinicians to make decisions regarding
nutritional care. If control patients got referred for a diet-
etic advice, then they were offered the same nutritional
care plan as the intervention group only for the period of
their hospitalization but received no post discharge follow
up care.
Time horizon
The costs between the two groups were compared over a
period of three months from the time of randomization
during hospital admission until the last follow-up.
Discount rates
Discounting of costs and effectiveness measures was not
performed, because the time horizon of this study did
not exceed 1 year [16].
Choice of nutritional/health outcomes
The primary nutritional outcome in this study, as was
the case in the clinical study [12] and for the sake of
maintaining consistency, was the unit improvement in
the PG-SGA over the 3-month study period. The sec-
ondary outcome was QALYs gained over the same
period and based on the responses to the EuroQoL 5 Di-
mensions 5 Levels (EQ-5D-5 L) [17].
PG-SGA
The nutrition status of the participants was confirmed
with PG-SGA by an experienced dietitian. The PG-SGA
[18] generates a numerical score while also providing an
overall global rating divided into three categories: well
nourished (PG-SGA A), moderately malnourished or sus-
pected of being malnourished (PG-SGA B) or severely
malnourished (PG-SGA C). For each component of the
PG-SGA, points (0–4) are awarded depending on the
impact on nutritional status. Component scores are
summed up to obtain total scores that range from 0 to 35
and scores ≥7 indicating a critical need for nutritional
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intervention and symptom management in the older pa-
tients [19]. PG-SGA has been validated in various settings
including older hospitalized patients and has a high sensi-
tivity and specificity to diagnose malnutrition [19].
HRQoL and QALYs
QALYs gained were chosen as an outcome as they facili-
tate comparisons between interventions for disparate
services and are recommended for use by decision
makers including the Pharmaceutical Benefits Advisory
Committee (PBAC) in Australia [20].
QALY estimates, calculated using the area-under-the-
curve method [16], were based on responses to the EQ-
5D-5 L which were scored using UK value sets [17].
The EQ-5D-5 L is a self-reported questionnaire and
measures a patient’s health across five different domains:
mobility, self-care, usual activities, pain/discomfort and
anxiety/depression [21]. Using these responses, the EQ-
5D-5 L is able to distinguish between 3125 states of
health. A UK-specific algorithm developed using time-
trade-off techniques was used to convert the EQ-5D-5 L
health description into a valuation ranging from − 0.281
to 1 [17]. Scores less than 0 represent health states that
are worse than death [22]. The EQ-5D-5 L has been vali-
dated in different clinical populations including patients
with multiple chronic illnesses, rehabilitation and ortho-
pedic patients awaiting joint replacement surgery and has
been found to have a stronger convergent validity coeffi-
cient (Spearman’s coefficient 0.51–0.75) and a higher
absolute informativity (Shannon’s index) as compared to
the EuroQol 5 Dimensions 3 Levels (EQ-5D-3 L) [23–25].
Measurement of effectiveness
No effectiveness data were obtained from secondary
sources as our analysis relied upon data from our ori-
ginal trial [12].
Estimating resources and cost
Data on the volume and total costs of healthcare utilisa-
tion, measured from the health care perspective, were
readily provided by Medicare Australia. Cost data were
provided in the form of Medicare Benefits Schedule
(MBS) data (number and costs of GP visits, specialist at-
tendances, non-specialist attendance, diagnostic proce-
dures and other medical services such as pathology and
teleheath services); Pharmaceutical Benefits Schedule
(PBS) data (quantity and costs of pharmaceuticals) and;
centralised costing (Australian refined diagnosis related
group (AR-DRG)) data [26] (number and costs of public
hospital inpatient episodes). Patient consent was sought
before obtaining MBS, PBS and AR-DRG data. Costs as-
sociated with the intervention itself (primarily dietitian
staff costs for making follow-up telephone calls (30 min
per month for two months i.e. two phone calls per
patient for all patients) and costs of supplements for
the entire study period for nearly half (36) of the pa-
tients) were estimated by combining staff time spent/
number of supplements provided and published infor-
mation on wage rates obtained from published re-
sources ($37.16 per hour for an accredited dietitian)
and unit costs for supplements sourced from hospital
accounts records ($6 per package per day). All costs are
reported in Australian dollars at 2016/17 unit prices [16].
Analytical methods
Descriptive statistics
Continuous variables were expressed as mean (standard
deviation (SD)) values or median (interquartile (IQR))
ranges and were compared using an appropriate paramet-
ric (Student t) test or nonparametric (Mann-Whitney U)
test. Categorical variables were expressed as frequencies
and percentages and were compared using Chi-square (χ2)
statistics or Fishers exact test as appropriate. Length of
hospital stay (LOS) was adjusted for in-hospital mortality.
Economic evaluation
Two types of economic evaluation (CEA and CUA) were
used in this study. Their choice was informed by the types
of outcomes measured in the main trial [12]. CEA is a
type of economic evaluation whose outcomes are
expressed in terms of natural units such as life expectancy
or change in PG-SGA scores, while outcomes in CUA are
reported in terms of QALYs [27]. Consequently, the pri-
mary outcome of this evaluation was expressed in terms
of incremental costs per unit improvement in PG-SGA
(CEA) and the secondary outcome reported in terms of
incremental costs per QALYs gained (CUA). An incre-
mental approach was used in order to determine, where
appropriate, the incremental cost effectiveness ratios
(ICERs) expressed as the incremental cost per unit im-
provement in the PG-SGA (primary outcome) and
incremental costs per quality adjusted life year QALY
gained (secondary outcome). The ICERs were calculated
as incremental costs divided by incremental changes in
outcomes. The economic evaluation was conducted using
an intention-to-treat approach.
Within-trial economic evaluation with respect to the
primary and secondary outcomes was undertaken
allowing for bivariate uncertainty with bootstrapping of
participant costs and outcomes to maintain the covari-
ance structure. To account for uncertainty due to
sampling variation in cost-effectiveness/cost-utility, non-
parametric bootstrapping [28] were applied on partici-
pant level data to derive 5000 paired estimates of mean
differences in costs and outcomes. These boot-
strapped pairs were summarized within cost effective-
ness planes (CEPs) [29]. The probability of the
intervention being more cost effective, compared to
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the usual care arm at different willingness-to-pay
thresholds, was depicted using Cost effectiveness
acceptability curves (CEACs).
Due to the presence of missing data on costs and out-
comes (Tables 1, 2 and 3), multiple imputation was used
to account for missing values prior to conducting the
base-case economic evaluation [30]. Imputed values
were generated by use of an iterative Markov chain
Monte Carlo method premised on multivariate normal
regression. To appropriately characterize the uncertainty
about the right value to impute, each missing value in
the dataset was replaced with a set of 50 plausible
values. Standard complete-case procedures were then
applied to each of the 50 resultant multiply imputed
datasets before combining the results using Rubin’s
rules [31]. The following variables were used to pre-
dict missing values in the imputation procedure:
study arm, age, gender, cognitive status, length of
stay, total number of comorbidities and malnutrition
diagnosis. In both the base-case and sensitivity ana-
lyses, only adjusted outcomes (adjusted for baseline
differences and correlation between repeated mea-
surements) were used.
Sensitivity analyses were carried out to test the robust-
ness of the base case results and they focused on evalu-
ating the effect of missing cost and outcome data values
on the economic evaluation results (i.e. comparing re-
sults based on complete cases and those estimated using
multiple imputed values). All analyses were conducted
in Microsoft Excel (2010) and Stata version 14.1.
Results
Descriptive statistics
A total of 1668 patients (Fig. 1) admitted to the De-
partment of General Medicine were assessed for par-
ticipation in this study, whereof 892 met the
inclusion criteria. Of the 892, 744 patients refused to
participate due to various reasons (Fig. 1). One hun-
dred and forty eight patients were therefore recruited
and randomized to the control (n = 70) and interven-
tion (n = 78) groups. The baseline clinical characteris-
tics (Table 1) were similar between the two groups
with regard to age, gender distribution, Charlson co-
morbidity index, number of medications and principal
clinical diagnosis. There was no difference in severity
of malnutrition at baseline as determined by PG-SGA






Age, mean (95% CI), y 81.6 (79.5 to 83.6) 82.0 (80.0 to 83.9) 0.76
Gender, n (%)
Male 23 (32.9) 31 (39.7)
Female 47 (67.1) 47 (60.3) 0.38
Residence before admission, n (%)
Home 66 (94.3) 68 (87.2) 0.11
Nursing Home 4 (5.7) 10 12.8)
Cognition, n (%)
Normal 67 (95.7) 74 (94.9) 0.56
Impaired 3 (4.3) 4 (5.1)
No of co-morbidities, mean (95% CI) 6.3 (5.6 to 6.9) 6.1 (5.5 to 6.6) 0.64
Charlson index, mean (95% CI) 2.3 (1.9 to 2.8) 2.2 (1.8 to 2.7) 0.82
Medications at admission, mean (95% CI) 10.1 (9.0 to 11.2) 8.8 (7.8 to 9.7) 0.07
Principal diagnosis at admission, n (%)
Respiratory 29 (41.4) 20 (25.6) 0.30
Cardiovascular 8 (11.4) 14 (18.0)
Falls 10 (14.3) 13 (16.7)
CNS 3 (4.3) 6 (7.7)
Miscellaneous 20 (28.6) 25 (32.1)
BMI, mean (95% CI), kg/m2 21.8 (20.7 to 22.8) 20.6 (19.7 to 21.5) 0.09
PG-SGA score, mean (95% CI) 13.3 (12.2 to 14.5) 12.1 (11.0 to 13.2) 0.11
EQ-5D-5 L index 0.6746 (0.617 to 0.729) 0.6934 (0.638 to 0.746) 0.62
Abbreviations: CI Confidence Interval, CNS Central Nervous System, BMI Body Mass Index PG-SGA, Patient Generated Subjective Global Assessment, EQ-5D-5 L
EuroQol 5 Dimensions 5 Levels
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score and HRQoL as determined by EQ-5D-5 L was
similar between the two groups (Table 1). Nutritional
intervention provided an additional mean 655 (95%
CI: 587.3 to 772.1) kcal of energy and 36.5 (95% CI:
31.5 to 41.5) grams of protein and 73% and 77.2%
patients were compliant with the intervention at
1 month and 2 months post-discharge, respectively.
Length of hospital stay (LOS) was significantly shorter
in the intervention patients (9.9 (SD: 7.2)) vs. 6.9 (SD:
5.3), P < 0.005) days, in control and intervention
groups, respectively (Table 3).
Incremental costs and outcomes
Base case analysis results
Table 2 presents a breakdown of mean healthcare costs
per participant over a 3 months follow-up period. In the
base case, mean per participant total Australian Medi-
care costs were lower in the intervention group com-
pared to the control arm (by $907 per patient) but these
differences were not statistically significant (95% CI:
-$2956 to $4854). The main drivers of the higher costs
in the control group were higher inpatient ($13,882 ver-
sus $13,134) and drug ($838 versus $601) costs. When
Table 2 Mean costs per patient (AU $)
Costsa Control Intervention Difference (Bootstrapped 95% CI)
Base Case Analysis (imputed cases)b n Mean n Mean
3 month MBS costs
GP Costs 70 347 (38) 78 311 (32) −37 (− 134, 59)
Specialist Attendance Costs 70 20 (5) 78 12 − 7 (− 19, 4)
Non-Specialist Attendance Costs 70 251 (43) 78 243 (36) − 8 (− 122, 100)
Diagnostic Procedures costs 70 200 (40) 78 197 (31) −4 (−111, 94)
Other Medical Service costsc 70 396 78 253 (34) − 143 (− 291, 2)
Total MBS costs 70 1216 (128) 78 1008 (97) − 208 (− 529, 149)
3 month PBS costs
Total drug costs 70 838 (186) 78 601 (57) − 237 (− 703, 47)
3 month Inpatient (DRG) costs
Total DRG costs 70 13,882 (1390) 78 13,134 (1439) − 748 (− 4584, 3310)
Intervention costs
Total intervention costs 70 0 78 286 (30) 286 (225, 352)
Total Costs 70 15,936 (1397) 78 15,029 (1430) −907 (− 4854, 2956)
Sensitivity analysis (complete cases)d
3 month MBS costs
GP Costs 62 348 (43) 65 307 (39) −41 (− 151, 92)
Specialist Attendance Costs 62 21 65 13 −9 (− 20, 8)
Non-Specialist Attendance Costs 62 247 (48) 65 251 (48) 4 (−108, 142)
Diagnostic Procedures costs 62 200 (42) 65 211 (39) 10 (−108, 121)
Other Medical Service costsc 62 389 (73) 65 248 (47) −141 (− 334, 5)
Total MBS costs 62 1205 (143) 65 1029 (132) −176 (− 495, 226)
3 month PBS costs
Total drug costs 59 855 (217) 65 610 (65) − 245 (− 832, 99)
3 month Inpatient (DRG) costs
Total DRG costs 70 13,882 (1390) 78 13,134 (1439) −748 (−3310, 4584)
Intervention costs
Total intervention costs 70 0 78 286 (30) 286 (225, 352)
Total Costs 59 17,024 (1595) 60 12,078 (917) −4947 (−9030, −1451)
aMBS Medicare Benefits Schedule, PBS Pharmaceutical Benefits Schedule, DRG Australian Refined Diagnosis Related Groups (AR-DRGs) cost weights used to cost
hospital admissions, GP General Practioner, Total costs =MBS costs + PBS costs + DRG costs + Intervention costs
bMultiply imputed values. Multiple imputations carried out to account for up to 29 or 19% missing data on cost estimates
cExamples of other medical costs include pathology and telehealth services as well as allied-health care attendances
dAnalysis restricted to non-missing total cost estimates (119 or 81%)
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the adjusted outcomes in the base case were considered
(Table 3), the intervention was more effective than the
control with participants in this arm reporting unit im-
provements in the PG-SGA that were higher by
1.3238 units (95% CI: 0.0240 to 2.3858) and QALYs that
were higher by 0.0050 QALYs gained per patient (95%
CI: -0.0079 to 0.0199). In line with best practice guide-
lines [32, 33], ICERs relating to both the primary and
secondary outcomes are not presented, as the interven-
tion was both cheaper and more effective regardless of
outcome considered.
The CEPs in the base case analysis (Fig. 2) shows
some uncertainly in the cost-effectiveness results but
most of the bootstrapped paired estimates of mean
differences in costs and outcomes appear in south-
east and south-west quadrants.
The CEACs (Fig. 3) show that the probability of the
intervention being cost-effective at willingness to pay
values as low as $1000 per unit improvement in PG-
SGA scores was above 98% while it was 78% at a willing-
ness to pay of $50,000 per QALY gained, the implicit
cost-effectiveness threshold used in Australia [34].
Sensitivity analysis results
In the base case analysis, multiple imputation was used
to deal with the missing data on costs (29 observations
or 20%), PG-SGA scores (45 observations or 30%) and
EQ-5D-5 L responses (19 observations or 13%). In the
sensitivity analysis, ignoring the missing data and using
complete case analysis (Tables 2 and 3) did not have an
effect on the incremental effectiveness. This is because
the intervention was still more effective by 0.9849 units
Table 3 Outcomes of study
Outcomesa Control Intervention Difference (Bootstrapped 95% CI)
n Mean n Mean
Base Case Analysis (imputed cases)b
EQ-5D-5 L and QALY gains
EQ-5D-5 L at baseline 70 0.6746 (0.0284) 78 0.6934 (0.0276) 0.1088 (−0.0489, 0.0916)
EQ-5D-5 L at 3 months 70 0.5787 (0.0407) 78 0.6358 (0.0349) 0.0571 (−0.0556,0.1560)
Unadjusted QALYs 70 0.1578 (0.0064) 78 0.1659 (0.0067) 0.0081 (−0.0090, 0.0265)
Adjustedc QALYs 0.005 (−0.0079, 0.0199)
PG-SGA Scores
PG-SGA Scores at baseline 70 13.3286 (0.5817) 78 12.1123 (0.4951) −1.2163 (− 2.6163,0.1793)
PG-SGA Scores at 3 months 70 7.3770 (0.4098) 78 5.9136 (0.4054) −1.4634 (− 2.4801, −0.1896)
Unadjusted improvement in PG-SGA Scoresd 70 5.9516 (0.6594) 78 6.1987 (0.5547) 0.2471 (−1.4931, 1.8661)
Adjustedc improvement in PG-SGA Scoresd 1.3238 (0.0240, 2.3858)
Inpatient stay
LOS in days 69 9.9 (7.2) 71 6.9 (5.3) 3.0 (0.9, 5.1)
Sensitivity analysis (complete cases)e
EQ-5D-5 L and QALY gains
EQ-5D-5 L at baseline 69 0.6736 (0.0290) 77 0.6926 (0.0272) 0.0189 (−0.0537, 0.1003)
EQ-5D-5 L at 3 months 60 0.5672 (0.0487) 69 0.6360 (0.0407) 0.0688 (−0.0553, 0.2043)
Unadjusted QALYs 59 (0.1553 (0.0076) 69 0.1658 (0.0075) 0.0105 (−0.0096, 0.0291)
Adjustedc QALYs 0.0060 (−0.0086, 0.0216)
PG-SGA Scores
PG-SGA Scores at baseline 69 13.3478 (0.5848) 74 12.0946 (0.5240) −1.2532 (−2.9491, 0.2727)
PG-SGA Scores at 3 months 46 6.9783 (0.6167) 57 5.8070 (0.5185) −1.712 (−2.7446, 0.3698)
Unadjusted improvement in PG-SGA Scoresd 46 6.1739 (0.8876) 57 5.8596 (0.7081) −0.3143 (− 2.4223, 1.8485)
Adjustedc improvement in PG-SGA Scoresd 0.9849 (−0.5601, 2.5912)
aEQ-5D-5 L EuroQoL 5 Dimensions 5 Levels, QALY Quality Adjusted Life Years, PG-SGA Patient Generated Subjective Global Assessment, LOS Length of
Hospital Stay
bMultiply imputed values. Multiple imputations carried out to account for up to 12% of the EQ-5D-5 L utility scores (2 or 1% of baseline and 19 or 1% of 3-month
EQ-5D-5 L scores)
cThese scores have been adjusted for baseline differences
dThese PG-SGA scores were reverse scored so that a positive score reflects an improvement in nutrition status
eTrial participants with complete information on baseline and 3-month outcomes
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of improvement in the PG-SGA score (95% CI: -0.5601
to 2.5912) and by 0.0060 QALYs gained per patient (95%
CI: -0.0086 to 0.0216), but was even more cheaper per
patient (by $4947, 95% CI: $1451 to $9030). These fig-
ures did not change the final interpretation because the
intervention still outperformed the control.
Discussion
The findings of this study indicate that, in older general
medical malnourished patients, the health care costs
were lower while nutrition status and HRQoL was better
among those in the individualized nutrition intervention
arm compared to those in the group that received usual
care with no post discharge dietetic follow-up. The dif-
ferences in costs and HRQoL outcomes were however
not statistically significant. In line with best practice
guidelines [35, 36], therefore, our analysis focused on de-
termining the likelihood of the intervention being cost-
effective as opposed to hypothesis testing relating to
whether the cost and QALY differences were statistically
Fig. 1 Study flow diagram
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significant. Our results show that probability of the
intervention being cost-effective at willingness to pay
values as low as $1000 per unit improvement in PG-
SGA was > 98% while it was 78% at a willingness to
pay $50,000 per QALY gained. One of the strengths
of this study is the use of PG-SGA for nutritional as-
sessment, which has been demonstrated to have high
sensitivity and specificity for the diagnosis of malnu-
trition and has been recommended as a predictive
tool for clinical outcomes [14]. Yet, very few costing
studies have utilized this stool for nutritional
assessment.
At least two reasons may explain the statistically insig-
nificant cost and HRQoL differences between the two
trial arms. The first may be because the original trial
[12] from which the data for this study were obtained
was not powered to detect differences in costs and
HRQoL, a result seen elsewhere [35, 36]. Another reason
specific to HRQoL could be a short duration of nutrition
intervention in our study. The impact of nutrition
b
a
Fig. 2 Cost-Effectiveness Planes
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intervention on utilities is complex and may not be evi-
dent after a short period of intervention. After initiating
nutrition intervention the temporal pattern that usually
follows is - first improvement in nutrition parameters like
weight then functional outcomes and lastly improvement
in HRQoL [37]. Future nutrition intervention trials of suf-
ficiently long duration may help verify this hypothesis.
The intervention was shown to have had lower mean
Medicare costs than the control.
The cost drivers for the higher mean costs per pa-
tient in the control group were higher inpatient and
drug costs. This could be related to the overall signifi-
cantly longer length of hospital stay for the control pa-
tients with resultant higher utilization of health care
resources. Studies have suggested that malnutrition
contributes to the development of new complications
such as delirium [38], predisposes to pressure ulcers
[39] and increases risk of falls [40], all of which may
contribute to the prolongation of the duration of
hospitalization. Early nutrition intervention on the
other hand may quickly improve the protein status and
hence muscle function [41] as reflected by an increase
in handgrip strength [42] and may lessen the risk of
hospital acquired infections and may contribute to fas-
ter resolution of delirium [43]. It is possible that exten-
sion of this intervention following hospital discharge
was associated with a sustained improvement in the
nutrition status of intervention patients with a conse-
quent reduction in the ‘post-hospital syndrome’ [44].
This may have led to a reduction in the utilization of
a
b
Fig. 3 Cost-Effectiveness Acceptability Curves
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primary health care resources (e.g. reduced GP visits)
with consequent reduction in overall costs.
Our results are in line with a meta-analysis by Russell
et al. [3] who found that use of ONS in surgical and eld-
erly medical patients both in hospital and community
settings can reduce LOS and complications with result-
ant net cost savings per patient. Our study is different
from the studies used in the above meta-analysis in that
we used a nutritional intervention tailored to individual
patients needs rather than ONS alone, as studies have
suggested poor compliance with ONS [45], especially in
the older population. Similarly Gianotti et al. [46] found
reduced treatment costs in patients who received enteral
nutrition among patients undergoing major abdominal
or cancer surgery and hypothesized that nutrition ther-
apy helps improve splanchnic microperfusion with re-
sultant lesser number of post-operative complications
but in contrast to our study, this study included only
surgical patients and limited nutrition intervention to
the perioperative period. Norman et al. [47] in their study
in malnourished patients aged 50.6 ± 16.1 years, with be-
nign gastrointestinal disease found that 3-month nutri-
tional supplementation with ONS increased HRQoL and
was cost-effective from a German statutory health insur-
ance perspective. Unlike our study, which included older
patients with multiple comorbidities, however, this study
was restricted to a relatively younger population of pa-
tients with benign gastrointestinal disease and nutrition
intervention commenced only at the time of discharge.
Our study results are also in line with the findings of three
recent meta-analyses conducted in different patient
groups [9–11], which suggest that the use of enteral med-
ical nutrition in the management of disease related malnu-
trition (DRM) can be an efficient intervention from a
health economic perspective and may lead to cost-savings.
Although malnutrition is common in older hospital-
ized patients, it is often poorly recognized by the
clinicians with resultant fewer malnourished patients
receiving treatment [48]. Economic evaluation offers a
framework within which complex changes can be syn-
thesized to aid in policy making. Our finding suggest
that if similar intervention were to be delivered to all
malnourished patients ≥60 years of age in General Med-
ical service of our hospital in 2015–16, a per-patient cost
saving of $907 will translate to a total savings of $1.86
million and if applied to the State of South Australia
total cost savings of $9.05 million can be achieved. This
study suggests that there is an opportunity to improve
the health of malnourished older patients at a low mar-
ginal cost. Very few interventions have achieved health
gains in this population at a lower cost [49]. In the
current climate of economic constraints in healthcare,
this study provides convincing evidence of the economic
benefits of nutrition intervention.
Limitations of study
Although the use of a randomized controlled study
provides robust evidence for assessing the utility of nu-
trition intervention, this study had limitations when
assessing economic value. Our analysis did not consider
several factors, which could bias the results by either
underestimating or overestimating the cost-effectiveness
of nutritional supplementation. While we included the
direct medical costs, we did not consider broader or in-
direct costs such as those borne by patients and their
families privately or by nursing homes and costs associ-
ated with loss of work due to periods of absence for pa-
tients or their carers. Additionally, our study duration is
limited to 3 months and long-term impact of such a nu-
trition intervention is unknown. Our study did have
missing data on some costs and outcomes, however
principled and robust methods were used to deal with
the missingness. Finally, the difference in QALY gains in
this study can be considered to be small and therefore
our result on the effectiveness should be interpreted
with caution. The overall economic evaluation results
nevertheless considered these QALY gains jointly with
cost differences as is appropriate.
Due to differences in design and organization of
health-care systems, our study results cannot be general-
ized to other settings and countries and further studies
are needed to contribute to the evidence of cost utility
of nutritional therapy.
Implications
Our study adds clinical and economic evidence of the
benefits of initiating an early nutrition intervention with
continuation in the community to improve health out-
comes in older hospitalized malnourished population
and justifies allocation of resources to improve the nutri-
tion status of an elderly population.
Conclusion
For both primary (change in PG-SGA scores) and
secondary outcomes (QALY gains), the results of our
health economic analysis suggest that the use of early
and extended nutritional intervention in older general
medical patients is likely to be cost-effective in the
Australian health care setting as the intervention was
both cheaper and more effective than the comparator.
This conclusion was supported further by results of the
CEACs that showed that the intervention had a high
likelihood of being the cost-effective option over a range
of willingness to pay values.
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